Bone sarcoma
Revision as of 01:19, 10 May 2019 by Warner-admin (talk | contribs) (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence" to "{| class="wikitable" style="width: 50%; text-align:center;" !style="width: 25%"|Study !style="width: 25%"|Evidence")
| Section editor | |
|---|---|
 |
James L. Chen, MD, MS The Ohio State University Columbus, OH |
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
ESMO
NCCN
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Giant-cell tumor of bone, all lines of therapy
Denosumab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Thomas et. al 2010 | Phase II |
Chemotherapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive medications
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
28-day cycles, given until complete tumor resection, progression of disease, or patient choice
References
- Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed
Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy
- Malignant fibrous histiocytoma (MFH) of bone has been treated with osteosarcoma regimens